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CC BY-NC-ND license (http://creativeAbstract FOXA1 (also known as hepatocyte nuclear factor 3a, or HNF-3a) is a protein of the
FKHD family transcription factors. FOXA1 has been termed as a pioneer transcription factor
due to its unique ability of chromatin remodeling in which the chromatin can be de-
compacted to allow genomic access by nuclear hormone receptors, including androgen recep-
tor (AR) and estrogen receptor (ER). In this review, we discuss our current understanding of
FOXA1 regulation of prostatic and non-prostatic AR-chromatin targeting. We present an up-
dated model wherein FOXA1:AR equilibrium in the nuclei defines prostatic AR binding profile,
which is perturbed in prostate cancer with FOXA1 and/or AR de-regulation. Finally, we discuss
recent efforts in exploring new horizons of AR-independent functions of FOXA1 in prostate can-
cer and interesting directions to pursue in future studies.
Copyright ª 2015, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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FOXA1 in prostate cancer 145mutant, which manifests in the foregut and hindgut being
replaced by ectopic head structures.3 Like other forkhead
(FKHD) family proteins, FOXA1 controls gene transcription
by directly binding to its consensus sequence, the FKHD
motif. In addition, FOXA1 has been shown capable of
opening surrounding chromatin and subsequently allowing
other transcription factors, such as androgen receptor (AR),
to come in close proximity to their target sites and thus
exert transcriptional control of gene expression.4e7
Although this transcription regulatory effect of FOXA1 is
quite well understood, important new developments have
been made recently concerning the functional roles of
FOXA1 in prostate cancer. This review thus discusses cur-
rent literature regarding the delicate mechanisms by which
FOXA1 regulates AR signaling and the deregulation and
implication of FOXA1 in prostate cancer progression.FOXA1 in development
FOXA1 was initially discovered approximately 25 years ago
as an important liver-enriched transcriptional regulator of
hepatic differentiation, since it was found to occupy the
promoters of liver genes a1-antitrypsin and transthyretin.8
Subsequent mouse studies have shown that Foxa1 expres-
sion can be observed in endoderm-, mesoderm- and
ectoderm-derived tissues of adult mice.9 It has been re-
ported that detectable Foxa1 mRNA could first be observed
at E7 in the late primitive streak stage in the midline
endoderm of mouse embryos, following that the expression
could be seen in the notochord, neural plate and floor plate
of the neural tube, indicating that Foxa1’s roles can range
from establishment of definitive endoderm to formation of
neural tube patterning.10e12
Although Foxa1 null mice don’t exhibit discernible
morphological defects, they display severe growth retar-
dation and die between postnatal days 2 and 14 (P2 and
P14), which is resulted from a combination of phenotypes
including dehydration and hypoglycemia.13,14 Therefore,
these observations indicate that FOXA1 plays a pivotal role
in the maintenance of glucose homeostasis and pancreatic
islet function. Tissue-specific deletion of Foxa1 in the
pancreas shows that FOXA1 and FOXA2 jointly regulate the
expansion of pancreatic primordial, specification of endo-
crine and exocrine compartments, and maturation of islet
cells.15 Similarly, there is also evidence that FOXA1 is
important for lung development by regulating respiratory
epithelial differentiation,16 and that it acts in a comple-
mentary manner with FOXA2 to ensure proper branching
morphogenesis of the lung.17 Moreover, it has been
demonstrated that both FOXA1 and FOXA2 in conjunction
are required for initiating the onset of hepatogenesis and
hepatic specification.18 More recently, a study utilizing
conditional knockout of Foxa1 and Foxa2 in dopamine
neurons reports that both factors are required for dopa-
mine neuron maintenance and that their loss can give rise
to locomotor deficits resembling the manifestations of
Parkinson’s disease.19 Taken together, mice studies
corroborate the notion that FOXA1 has critical influence on
organogenesis.
In particular, a number of papers have demonstrated the
significance of FOXA1 during development of the prostateand mammary glands. It has been said that the mammary
ductal morphogenesis, but not the alveolar lineage, is
dependent on FOXA1, and that while Foxa1-null glands can
form milk-producing alveoli, they have lost ERa expression
and functional activity, which ultimately result in compro-
mised ductal lineage specification.20 Likewise, in the
prostate, FOXA1 deficiency leads to abolished differentia-
tion and maturation of luminal epithelial cells.21 Initially
derived from the hindgut endoderm, the mouse prostate
epithelium has persistent Foxa1 expression throughout the
processes of prostate development, growth, and adult dif-
ferentiation.22 The origin of the prostate is the urogenital
sinus, which is a midline structure composed of an
endoderm-derived epithelial layer and a mesoderm-derived
mesenchymal layer.23 In the mouse, at approximately
E17.5, prostatic morphogenesis starts to take place,
prompted by responsiveness to circulating androgens and
induction of AR activity.23 During the course of develop-
ment, Foxa1 expression was characterized in all lobes of
the murine prostate, and is specifically enriched in AR-
expressing epithelial cells. FOXA1 plays a critical role in
modulating AR-regulated transcriptional signaling in pros-
tate epithelial cells,6 and concordantly Foxa1-deficient
prostate has severely impaired ductal pattern formation,
due to inhibition of ductal canalization and epithelial
cytodifferentiation.21 As a consequence, the Foxa1-null
prostate lacks structural maturity as well as secretory ac-
tivities. Taken together, there is compelling evidence that
FOXA1 is critically involved in growth and differentiation of
prostatic cells and is required for prostate glandular
morphogenesis.FOXA1 deregulation in prostate cancer
As FOXA1 is highly involved in developmental processes and
lineage specification in several organs, when expressed at
aberrant levels it may disrupt normal physiological events
and lead to formation of cancer. Molecular and genetic
studies have shown that FOXA1 is often found to be
abnormally expressed in a number of cancer types,
including acute myeloid leukemia (AML), lung, esophageal,
thyroid, breast and prostate cancers.24e30 At present, the
prevailing views on FOXA1 expression in prostate cancer
have not reached a consensus, with contrasting evidence
seen in different cohorts of cancer patients. Analyses of
human prostate cancer specimens have revealed that
FOXA1 is overexpressed in metastatic as well as castration-
resistant prostate cancer (CRPC) patients, but its expres-
sion is lower in normal and neoplastic transitional zone
tissues.31 In addition, the level of FOXA1 may be positively
correlated with conventional parameters indicative of
cancer progression (including tumor stage and Gleason
scores), and negatively correlated with relapse-free sur-
vival times.30,31 In other words, high FOXA1 level is asso-
ciated with poor prognosis. However, other studies have
also demonstrated that low FOXA1 levels are found in
metastatic and CRPC tumors and may in fact denote unfa-
vorable prognostic outcome in advanced prostate can-
cer.32,33 In order to reconcile these conflicting findings, the
function of FOXA1 should be carefully dissected with
respect to cellular context, taking into consideration the
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understand how FOXA1 may fit as a piece of jigsaw in the
prostate cancer puzzle.
In addition to deregulation at expression level, muta-
tions in the FOXA1 gene have also been uncovered in
prostate tumors (Fig. 1), as reported in recent literature34
as well as in TCGA (The Cancer Genome Atlas). Recurrent
FOXA1 gene mutations had recently been identified and
characterized in 5 of 147 prostate cancers, including both
localized as well as castration-resistant cases.35 Moreover,
4 of these 5 mutations are located in the C-terminal
transactivation domain, and mutated FOXA1 was demon-
strated to repress androgen signaling and augment tumor
growth.35 Another independent study also reported 3
different non-silent mutations residing in or close to the
forkhead domain in FOXA1,36 which are anticipated to
disrupt DNA binding, but to what extent and how it may be
related to prostate carcinogenesis will require further
studies. Moreover, a recent study reported that, by
adopting the methodology of 3D organoid culture system,
the genetic heterogeneity of prostate cancer could be
recapitulated, and FOXA1 was among the most mutated
genes in the organoid CRPC lines.37
Another level of FOXA1 deregulation in prostate cancer
is reflected in somatic mutations of its cis-regulatory ele-
ments, which in turn affects FOXA1 transcriptional activity.
It has been described that in prostate cancer there exists
single nucleotide polymorphism (SNP) within the consensus
forkhead motif, which is recognized and bound by the
FOXA1 protein (Fig. 1). A prevalent SNP was identified in
LNCaP prostate cancer cell line, which locates in the
proximal promoter of the gene encoding UDP glucur-
onosyltransferase 2B17 (UGT2B17).38 This G to AFigure 1 FOXA1 mutations in prostate cancer. Somatic mutation
CRPC tumors, as well as in prostate cancer cell lines (the latter show
prostate cancer risk have also been reported occurring within thepolymorphism, UGT2B17 e 155 G/A, also appearing in NCBI
SNP database as rs59678213, was shown to have a notable
impact on FOXA1 binding, with the A-containing allele
being 13-fold more active in luciferase assays.38 Moreover,
another study revealed an SNP significantly associated with
risk for prostate cancer in the chromosome 8q24 region
(rs183373024), where it disrupts the FOXA1 recognition
motif.39 As ChIP-seq data have reported AR and FOXA1
binding at this region in cell lines, it is predicted that this
particular SNP in prostate cancer may cause disruption of
FOXA1 and/or AR binding and thus lead to deregulation of
some tumor suppressor genes. Several candidate genes
were presented to be potential targets for this putative
SNP-containing FOXA1 enhancer, however chromatin
conformation capture (3C)-based techniques or CRISPR as-
says may be needed to assure the target gene.FOXA1 defines prostate lineage-specific AR
cistrome
Like other forkhead proteins, FOXA1 encompasses a winged
helix domain that is composed of three a-helices, three b-
sheets and two loops.40 This unique structure, which closely
resembles that of linker histones,41 has imparted to FOXA1
the ability of binding to highly compacted chromatin and
subsequently prying it open.42 In doing so, FOXA1 creates
an open and easily accessible chromatin conformation to
facilitate hormonal transcription factors such as estrogen
receptor (ER) and AR to bind their cis-regulatory ele-
ments.43 Comparison of FOXA1 cistromes between breast
and prostate cancer cells illustrates very distinct, lineage-
specific profiles, where less than 40% of binding sites ares of the FOXA1 gene that have been identified in localized and
n in blue, namely F266C, A340fs, P358fs). SNPs associated with
consensus sequence of FOXA1 binding motifs.
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the binding sites of AR and ER in prostate and breast cells,
respectively, suggesting that FOXA1 may be critical in
determining lineage-specific hormonal factor chromatin-
targeting. It has been shown that FOXA1 is essential for
AR-mediated prostatic gene activation, corroborated by
the facts that FOXA1 regulatory elements are found in the
core enhancer of the prostate-specific antigen (PSA) gene,
a prototypical AR target, adjacent to the androgen
response elements (AREs), and that perturbations in the
FOXA1 motif can significantly abolish induction of PSA by
androgens.6 Through bioinformatic and biochemical ana-
lyses, it has been discovered that the FKHD motif is
enriched in AR cistromes,45,46 and that FOXA1 can physi-
cally interact with AR.6 Thus, upon stimulation by andro-
gens, AR translocates into the nucleus and preferentially
binds cis-regulatory sequences that are largely pre-
occupied by FOXA1, potentially under the recruitment by
the FOXA1 protein. Expression profiling studies showed that
FOXA1 indeed positively regulates prostatic gene expres-
sion induced by androgen.47
The mechanisms by which FOXA1 recognizes lineage-
specific enhancers have also been investigated. It has been
reported that FOXA1 binding can be guided by specific
chromatin marks, namely mono- and di-methylation of
histone 3 lysine 4 (H3K4me1, me2).44 Both are epigenetic
signatures typically associated with enhancers, H3K4me1
and H3K4me2 genomic distribution was thought to provide a
blueprint for directing differential FOXA1 binding in a
lineage-specific manner. Furthermore, DNA methylation
has also been shown to play a part in defining FOXA1 binding
and enhancer activation. Genome-wide interrogation of
DNA methylation reveals that FOXA1-bound enhancers are
generally hypomethylated compared to juxtaposing
genomic regions, in a pattern which is also correlated with
cell type-specific FOXA1 binding.48 To better understand
the sequence of events occurring at FOXA1-activated en-
hancers, kinetics study showed that binding of FOXA1 to
chromatin could be detected prior to significant induction
of H3K4me2 and DNA demethylation, which suggests that
hypomethylation may be an epigenetic phenomenon suc-
ceeding FOXA1 binding rather than a pre-established
mark.48 Although DNA hypomethylation does not seem to
be required for FOXA1 binding, it is important for turning on
FOXA1 transcriptional activity, as shown in luciferase re-
porter assays which exhibited reduced enhancer activation
when constructs were methylated.48FOXA1 prevents unrestricted, non-prostatic AR
cistrome
Although FOXA1 pioneering of prostatic AR activities has
been extensively studied, much less is known regarding
aberrant AR programs in cancer cells, which often harbor
AR amplification or overexpression, and FOXA1 loss or
mutations. Whether and what cistrome AR binds in the
absence of FOXA1 remained unaddressed for a while and
have become questions of significance since the discoveries
of FOXA1 mutations and loss in prostate cancer.33,35,36,47
With more advanced sequencing technologies and scrupu-
lous analytic efforts, a recent study demonstrated thatFOXA1 is not only crucial for defining a prostate-specific AR
program, but notably is also imperative for obstructing
non-prostatic AR binding events.47 This latter feature is
reflected in the observation that FOXA1 depletion in pros-
tate cancer cells, instead of resulting in loss of total AR
binding events, rather leads to substantial gain of new AR
binding sites, reflecting AR reprogramming at the genome-
wide level.7,30,33,47,49 It was reported that silencing of
FOXA1 gave rise to a marked increase of over 2.5-fold in
the number AR occupied sites.30 By grouping AR binding
sites and target genes according to their relative responses
to FOXA1 depletion, three classes of AR regulatory regions
can be characterized: 1) sites that are independent of
FOXA1 and remain unchanged regardless of FOXA1 deple-
tion; 2) sites that require FOXA1 to open chromatin for AR
recruitment (prostate-specific); 3) sites that only become
bound by AR upon FOXA1 loss.30 Similar gain of AR binding
sites upon FOXA1 depletion was also reported by an inde-
pendent group.47 Our group performed motif analyses on
endogenous as well as reprogrammed AR binding sites and
showed that while in control cells a majority of the AR
binding sites contained primarily the FKHD motif, upon
FOXA1 knockdown this pattern became shifted towards
binding sites that are dominated by the ARE motif.47 These
gained ARE-mediated sites have not been pioneered by
FOXA1 and are bound by AR through direct recognition of
its consensus sequences, controlling a set of genes quite
distinct from its FOXA1-pioneered, prostate-specific tar-
gets. This notion is further supported by the findings that in
FOXA1-depleted cells, approximately half of the prostatic
androgen-regulated genes lose their androgen-
dependency, but more importantly, new sets of
androgen-dependent genes not seen in parental cells are
acquired.30 This set of new target genes may contribute to
enhanced cell growth and metabolism potentially leading
to prostate cancer progression.33 In addition, androgen-
regulated genes in control cells are typically enriched for
both AR and FOXA1, however in FOXA1-depleted cells, the
acquired new sets of androgen-regulated genes only
exhibited enrichment of binding sites unique to AR.30 Taken
together, whether FOXA1 will facilitate or inhibit AR
binding to specific genomic regions is context-dependent,
depending largely on the co-occurrence of FKHD and ARE
(or half ARE) motifs. It is clear that, in addition to its role in
pioneering prostate-specific AR binding events, FOXA1 at
the same time functions to inhibit AR binding to non-
prostatic genes, the latter being equally important as the
former in its ability to ensure prostate lineage
differentiation.FOXA1:AR equilibrium and prostate cancer
Previous studies have reported that even preceding
androgen stimulation FOXA1 could bind to DNA and occupy
a majority of AR-associated sites.30,33,44,47 As demonstrated
in one study, approximately 54% of AR binding sites were
shared by FOXA1 in androgen-treated LNCaP cells, and 70%
of these sites had FOXA1 pre-occupancy before hormone
treatment.33 These studies have also revealed that on a
global scale there exist a vastly more number of FOXA1
binding sites than AR; nearly 90% of FOXA1 binding sites are
148 Y.A. Yang, J. Yunot co-occupied by AR. These data suggest that 1) FOXA1
may regulate many target genes independently of AR
(which will be discussed in the next section) and 2) exten-
sive FOXA1 binding events may be necessary to ensure AR
binding to the prostate-specific genes. This latter point is
supported by the observation that FOXA1 knockdown leads
to AR re-distribution to many new sites.30,33,47 Using FAIRE-
seq (formaldehyde-assisted isolation of regulatory ele-
ments followed by massively parallel sequencing), a study
has reported that a significant proportion of FOXA1-bound
sites exhibited low FAIRE signals along with repressive his-
tone marks, reflective of a closed chromatin conformation,
implying that FOXA1 binding is insufficient for functional
activity of its bound enhancers.50 Moreover, we recently
delineated that FOXA1 opens up large number of chromatin
regions, only a portion of which, likely due to the co-
occurrence of a half or full ARE within, are bound by
AR.47 Our data suggest that, instead of directly fetching AR
to the desired sites, FOXA1 binds to FKHD sites to increase
the competence of any nearby half or full ARE sites for AR
binding, compared to those AREs located at less accessible
chromatin regions (Fig. 2).
One drawback of this system is that, when the amount of
FOXA1 is in great excess to AR in the nuclei, it will inevi-
tably dilute AR across the chromatin forming insignificant
binding. This was demonstrated using the Du145 model
system by manipulating overexpression of FOXA1 and AR in
different levels, since these cells have negligible amounts
of both endogenous proteins. As a result, moderate amount
of FOXA1 shifts AR binding from ARE to FKHD sites. How-
ever, when FOXA1 is abundantly available, it could open up
chromatin immensely, significantly increasing the number
of open chromatin regions detected by FAIRE-seq, to the
extent that AR binding becomes diluted across the entire
genome. Consequently, total specific AR binding events are
drastically reduced, since FOXA1 is able to direct AR to
numerous open sites which may not be accessible had
FOXA1 not been so abundantly present.47 Therefore, anFigure 2 FOXA1:AR equilibrium determines the AR binding
profile. The schematic model depicts that AR binds to ARE
motifs in the absence of FOXA1, is recruited to FKHD sites with
co-occurring full or half AREs when at equilibrium with FOXA1,
and is diluted across the chromatin to form insignificant bind-
ing by excessive FOXA1.equilibrium between nuclear FOXA1 and AR levels is critical
for the maintenance of the prostatic AR program.
The FOXA1:AR equilibrium may be disrupted in various
pathological conditions in prostate cancer. For example, in
patients being treated with hormone deprivation therapy,
there is markedly reduced nuclear AR level, leading to
excessive FOXA1 and inhibition of residual AR binding to
DNA. Therefore, FOXA1 knockdown in androgen-deprived
LNCaP cells ultimately allows AR to form some significant
binding events. Consistent with the changes in AR binding
profile, FOXA1 depletion was also found to increase sensi-
tivity to lower androgen levels, as measured by level of
prostate-specific gene transcription.30 It was observed that
androgen-induced genes become upregulated and
androgen-repressed genes downregulated simply following
FOXA1 knockdown, despite the lack of hormone stimula-
tion.47 In other words, FOXA1 loss turns on androgen-
independent AR transcriptional program, which might
highlight a potential route for the development of castra-
tion resistance in prostate cancer. These studies are in good
agreement with recent observations of FOXA1 loss-of-
function mutations in prostate cancer and downregulation
in CRPC.33,35 In addition, studies have shown that AR pri-
marily functions to promote G1-S cell cycle progression in
androgen-dependent prostate cancer requiring the chro-
matin remodeling actions of FOXA1.51e53 On the contrary,
in CRPC, AR function digresses to regulate G2-M transition
instead, by modulating expression of new target genes such
as UBE2C, a critical M phase checkpoint inhibitor.54
Importantly, the differential activities of AR are brought
about by FOXA1 recruitment to regulatory sites of these
genes prior to AR binding. Therefore, FOXA1 plays stage-
specific and context-dependent functions in its regulation
of particular AR program in either androgen-supplemented
or -deprived conditions.Role of FOXA1 in regulating prostate cancer cell
growth and motility
Overall, both oncogenic and tumor-suppressive roles have
been reported for FOXA1, which suggests that its precise
contribution to cancer development or progression may be
depended on disease stage, context, and treatment his-
tories. In conjunction with AR signaling in the presence of
androgen, FOXA1 is known to promote prostate cancer
proliferation by inducing expression of cell cycle genes.32,51
However, under androgen-depleted conditions, FOXA1 was
shown to rather inhibit cell proliferation and its loss led to
androgen-independent prostate cancer cell growth, being
consistent with its regulation of AR signaling.47 In support
with this tumor suppressor role, in mice with prostate-
specific Foxa1 gene deletion, progressive hyperplasia can
be observed, and Foxa1 knockout epithelial cells exhibit
increased proliferation and altered morphology.55 Further,
following castration, the number of Foxa1-positive cells
was significantly reduced, supporting Foxa1 loss as a po-
tential mechanism to castration resistance. Thus, like its
modulation of AR signaling, FOXA1 regulation of prostate
cancer cell growth is context-dependent.
Through analyses of genome-wide gene expression
profiling, it has been discovered that FOXA1 may also
FOXA1 in prostate cancer 149possess AR-independent functions in inhibiting cell motility
and epithelial-to-mesenchymal transition (EMT).32 In pros-
tate cancer cells lacking AR expression, ectopic introduc-
tion of FOXA1 is sufficient to impede cell invasion and
migration.32 On the other hand, loss of FOXA1 in LNCaP cells
increases cell invasiveness, both in androgen-containing
and -deprived conditions. Both cases demonstrated the
AR-independent function of FOXA1 in inhibiting prostate
cancer cell motility. Meanwhile, it is also found that FOXA1
can negatively regulate EMT, and loss of FOXA1 in LNCaP
cells results in an astrocyte-like, fusiform, or fibroblastic
phenotype characteristic of mesenchymal and neuroendo-
crine cells. Further analysis revealed that among direct
transcriptional targets of FOXA1, SLUG was identified to be
a key repressed gene that confers the anti-motility prop-
erties associated with FOXA1.32 Similar functions of FOXA1
in preventing metastasis have been reported in other forms
of cancer as well, such as lung cancer and pancreatic
cancer,56,57 supporting the idea that this anti-EMT role is
AR-independent. Being concordant with these functional-
ities, expression profiling datasets of prostate tumors
confirm that FOXA1 is upregulated from benign tissue to
localized tumor, but downregulated in metastatic CRPC
tumors compared to localized ones.32,33 However, there
exists contrasting histological evidence that FOXA1 level is
high in metastatic prostate cancer.58 FOXA1 expression
level may need to be more carefully looked at taking into
considerations of disease stage, hormone deprivation
treatment history, and relative AR level.Future directions
Despite these significant advances in our understanding of
FOXA1 regulation of AR signaling and prostate cancer, many
questions remain to be answered. Various mutations to the
FOXA1 gene have been reported in prostate cancer. It will
be critical in future studies to determine how these mu-
tants differ from the wildtype FOXA1 in their regulation of
AR signaling and prostate cancer progression. Further, the
controversies regarding FOXA1 expression in primary spec-
imens and its association with prostate cancer prognosis are
yet to be carefully addressed. Since FOXA1 promotes cell
growth in an AR-dependent manner, its expression level
may be associated with poor clinical outcome only in pa-
tients with primary prostate cancer that is not castration-
resistant. On the other hand, as FOXA1 is able to inhibit cell
motility in an AR-independent manner, its expression level
would predict good clinical outcome in patients who have
been subjected to androgen-deprivation therapies. Impor-
tantly, due to the significance of the equilibrium between
FOXA1 and AR levels, it will be imperative to take into
consideration the FOXA1/AR ratio when predicting disease
outcome. As FOXA1 loss has been shown to activate
androgen-independent AR signaling and contribute to CRPC
progression, a low FOXA1/AR ratio may be indicative of
poor prognosis. Moreover, very recently it is reported that
FOXA1 has a novel immunosuppressive function in T cells.59
It was shown that FOXA1 could be induced by interferon-b
(IFN-b), which is used in treatment of relapsing-remitting
multiple sclerosis (RRMS), an autoimmune disease where
regulatory T (Treg) cells are defective. Additionally,generation of FOXA1þ Treg cells upon IFN-b treatment was
found to associate with favorable clinical outcome in RRMS
patients. Thus, these data indicate that it would be inter-
esting to study whether the role of FOXA1 in T cells may be
implicated in prostate cancer and tumor microenviron-
ment. This will represent a new research direction of
FOXA1 quite distinct from its well-established function in
the AR context.
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